课题基金 / 基金详情

PROTOCOL TO EVALUATE TOXICITY, BIOLOGIC EFFECT AND EFFICACY OF ANTI-CD6-BR

PROTOCOL TO EVALUATE TOXICITY, BIOLOGIC EFFECT AND EFFICACY OF ANTI-CD6-BR
评估抗 CD6-BR 的毒性、生物效应和功效的方案
批准号：
3740045
负责人：
TIMOTHY KUZEL
金额：
$0.0万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/3740045
关键词：
clinical chemistry covalent bond dosage human subject human therapy evaluation immunoglobulin G inhibitor /antagonist intravenous administration lymphoma monoclonal antibody neoplasm /cancer chemotherapy pharmacokinetics ricin

项目摘要

项目成果

TIMOTHY KUZEL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is a Phase I open-label dose-escalation trial using Anti-CD6-blocked Ricin (Anti-CD6-bR) in the treatment of patients with cutaneous T-cell lymphoma(CTCL) Anti-CD-bR is an IgG2a murine monoclonal antibody which has veeb covalently linked to blocked ricin. Intravenous doses of Anti-CD6-bR will be given continuously for 5 days via central venous catheter. Serum pharmacokinetics will be obtained for analysis with the 1st dose administered. Serum Hm and HARA levels will be followed throughout treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
C3/C: Clinical Trials and Advocacy Core
Clinical Trials and Advocacy Core
NUY96H1--PHASE II TRIAL OF 9-AMINO CAMPOTHECIN IN CUTANEOUS T CELL LYMPHOMA
NUY96H1--PHASE II TRIAL OF 9-AMINO CAMPOTHECIN IN CUTANEOUS T CELL LYMPHOMA
海外基金